首页 / 院系成果 / 成果详情页

ShenQi FuZheng Injection combined with chemotherapy in the treatment of colorectal cancer: A meta-analysis 期刊论文

编号：

da7583ac-5f05-4bd4-84ec-f9ccea05ad18
作者：

Xu, Rongzhong(许荣忠)#^[1]Lin, Liubing(林柳兵)#^[2]Li, Yong^[2]Li, Yan*^[1]
语种：

英文
期刊：

PLOS ONE ISSN：1932-6203 2017 年 12 卷 9 期 ; SEP 27
收录：
摘要：

Objective
This study aims to investigate cellular immunity and clinical efficacy of ShenQi FuZheng Injection (SFI) in the associated chemotherapy of colorectal cancer (CRC).
Methods
PubMed, Cochrane Library, EMBASE, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Full-text Database (VIP), WanFang Database and Chinese Biomedical Literature Database (CBM) searches were undertaken to identify randomized controlled trials of SFI plus chemotherapy versus chemotherapy alone in CRC patients. The quality of each trial was assessed according to the Jadad's scale, and Review Manager 5 was used to statisitically analyze the outcomes.
Results
Eight studies involving 722 patients were included in this review. The meta-analyses suggested there was a significantly higher overall response rate (OR 1.89; CI: 1.10-3.24; p = 0.02), grades of KPS (OR 2.35; CI: 1.55-3.56; p<0.01), CD3+cells (MD 10.29; CI: 8.46-12.12; p<0.01), CD4+cells (MD 7.06; CI: 5.33-8.794; p<0.01), CD4/CD8+ cells (MD 0.32; CI: 0.25-0.40; p<0.01), NK+ (MD 7.20; CI: 2.02-12.37, p = 0.006), WBC (MD 1.24; CI: 0.59-1.89; p<0.01), HB (MD 14.55; CI: 7.47-21.63; p<0.01), and PLT (MD 19.05; CI: 4.29-33.81; p = 0.01), but lower severe toxicity for leukocytopenia (OR 0.37; CI: 0.17-0.80; p = 0.01), thrombocytopenia (OR 0.32; CI: 0.14-0.74; p = 0.008), gastrointestinal toxicity (OR 0.48; CI: 0.24-0.96; p = 0.04), when chemotherapy combined with SFI was compared with chemotherapy alone. There were similarities between two groups in liver dysfunction (OR 0.44; CI: 0.18-1.08; p = 0.07) and CD8+ (MD 0.54; CI: -1.89-2.96; p = 0.66). Also, there was presence of heterogeneity in the CD8 results; after the sensitivity analysis, the result of CD8+ was reversed (MD 1.57; CI: 0.32-2.81; p = 0.01). There was no significant publication bias across studies according to the Egger's (P = 0.19) and Begg's test (P = 0.23).
Conclusion
SFI enhances chemotherapy efficiency as they are combined and used in the treatment of colorectal cancer patients. At the same time, SFI also improves patients' immunity function.
推荐引用方式
GB/T 7714：

Xu Rongzhong,Lin Liubing,Li Yong, et al. ShenQi FuZheng Injection combined with chemotherapy in the treatment of colorectal cancer: A meta-analysis [J].PLOS ONE,2017,12(9).
APA：

Xu Rongzhong,Lin Liubing,Li Yong,Li Yan.(2017).ShenQi FuZheng Injection combined with chemotherapy in the treatment of colorectal cancer: A meta-analysis .PLOS ONE,12(9).
MLA：

Xu Rongzhong, et al. "ShenQi FuZheng Injection combined with chemotherapy in the treatment of colorectal cancer: A meta-analysis" .PLOS ONE 12,9(2017).
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：7  下载次数：0

分享到：

浏览次数：7

下载次数：0

打印次数：0